Self-administered inhaled methoxyflurane (Penthrox®) as pre-injection analgesia in Podiatry Outpatients: A blinded, randomised study.

Phase 4

Recruiting

• Conditions: pain; Anaesthesiology - Pain management; Public Health - Health service research

• Registration Number: ACTRN12623000936628
• Lead Sponsor: Claire Huxtable

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-08-30
• Last Update Posted: 9 September 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

o18 years of age and over
oA painful ingrown toenail which requires a minor surgical procedure
oAbility to self-administer methoxyflurane via a hand-held Penthrox® inhaler.

Exclusion Criteria

oA documented history of cognitive impairment or are otherwise unable to give informed consent
oAllergy to methoxyflurane or any other medication or agent required for the procedure
oA personal or familial history of malignant hyperthermia
oPrevious history of a significant head injury
oSignificant renal impairment (eGFR<60mL/min)
oSignificant cardiac or respiratory illnesses
oWomen who are pregnant, planning to become pregnant or breastfeeding
oPatients taking concurrent drugs with known clinically significant nephrotoxic effects (patients taking tetracyclines, aminoglycosides, colistin, amphotericin B, barbiturates, alcohol, isoniazid and rifampicin will be excluded).
oPatients who have received methoxyflurane on the day prior to the procedure or 15 mL (5 bottles) in the week prior to the procedure.
oNeurological Assessment: Absent protective sensation upon monofilament testing.
oVascular Assessment: Clinically significant Peripheral Arterial Disease.
oPatients who are not willing or able to fast for 6 hours prior to the planned procedure.

Study & Design

• Study Type: Interventional
• Study Design: Not specified